Stockreport

Cabaletta Bio Reports Third Quarter 2024 Financial Results and Provides Business Update

Cabaletta Bio, Inc.  (CABA) 
PDF – Clinical data from the RESET-Myositis™ and RESET-SLE™ trials, along with initial clinical data from the RESET-SSc™ trial, to be presented this weekend in oral and post [Read more]